Related Experiment Videos
Electron spin resonance studies on caeruloplasmin and iron transferrin in patients with chronic lymphocytic leukaemia
British Journal of Cancer
|March 1, 1980
Insights
Whole-blood caeruloplasmin levels are elevated in chronic lymphocytic leukaemia (CLL) patients, increasing with disease progression. Iron transferrin levels were only significantly raised in those with marrow failure.
Area of Science:
- Biochemistry
- Hematology
- Oncology
Background:
- Chronic lymphocytic leukaemia (CLL) is a heterogeneous lymphoid malignancy.
- Biochemical markers can aid in understanding disease progression and patient stratification.
Purpose of the Study:
- To investigate whole-blood caeruloplasmin and iron transferrin levels in patients with chronic lymphocytic leukaemia (CLL).
- To correlate these levels with disease stage, clinical involvement, and disease activity.
Main Methods:
- Whole-blood caeruloplasmin was measured using electron spin resonance.
- Iron transferrin levels were assessed in 41 CLL patients across various disease stages.
Main Results:
- Caeruloplasmin levels were elevated in all CLL stages, showing a positive correlation with clinical involvement.
- Progressive disease exhibited higher caeruloplasmin levels compared to inactive disease.
- Whole-blood iron transferrin levels were variable and significantly increased only in patients experiencing marrow failure.
Conclusions:
- Elevated whole-blood caeruloplasmin may serve as a potential biomarker for disease progression in CLL.
- Iron transferrin elevation is specifically associated with marrow failure in CLL patients.
- These findings contribute to understanding the biochemical landscape of CLL and its clinical manifestations.
Abstract:
Whole-blood caeruloplasmin measured by electron spin resonance was studied in 41 patients with chronic lymphocytic leukaemia. The levels were above normal at all stages of the disease, rose with increasing clinical involvement, and were higher in progressive than inactive disease. Whole-blood iron transferrin levels were more variable, and were significantly raised only in patients with marrow failure.